Special Issue

Macrophages in Health and Non-infectious Disease 2.0

Message from the Guest Editors

Having first been described more than 100 years ago, macrophages are still the focus of biomedical research. For about 50 years, they were considered solely as part of the defense against pathogens intruding an organism; however, unravelling the mechanisms of inflammatory reaction regulation made it clear that macrophages not only possess effector functions but also act as important regulators of inflammation. Apart from infectious diseases, it has been demonstrated that macrophages are actively involved in the pathogenesis of socially important non-infectious diseases, such as atherosclerosis, cancer, diabetes and others. These findings have expectedly led to the identification of macrophages as potential and highly attractive therapeutic targets. In this Special Issue, we want to collect the most recent publications on the mechanisms that macrophages use to regulate homeostasis and their involvement in the pathogenesis of non-infectious diseases. We also welcome research describing novel macrophage markers that reflect their functional state or are involved in macrophage tolerance and training as well as the interaction of macrophages with resident microbiomes.

Guest Editors

Dr. Alexei Gratchev

Prof. Dr. Alexander N. Orekhov

Dr. Evgeny E. Bezsonov

Deadline for manuscript submissions

closed (15 December 2021)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/80281

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).